Sudoscan (Electrochemical Skin Conductance) Diagnostic Performance and Evidence
Sudoscan uses electrochemical skin conductance (ESC) measured from hands and feet to quantify sudomotor (sweat gland) function. ESC is generated by an electrochemical method intended to reflect sweat gland sympathetic innervation and small-fiber/autonomic function. [1]
Scientific Basis for Sudoscan Measurements
Sudoscan measures ESC in microSiemens (µS) from hands and feet after transcutaneous electrochemical stimulation of sweat glands. [1] ESC is used clinically as a surrogate marker of sudomotor impairment, which is a frequent early manifestation of small-fiber neuropathy and autonomic neuropathy. [1]
Clinical Uses of Sudoscan
Sudoscan has been studied for detection and monitoring of neuropathies that involve small fibers and sudomotor dysfunction. [2] Key studied applications include diabetic peripheral neuropathy, small-fiber neuropathy, and hereditary transthyretin amyloid polyneuropathy with autonomic dysfunction. [1] [2] Sudoscan has also been investigated for chemotherapy-associated neuropathy, including bortezomib-induced painful neuropathy, using ESC profiles as an objective marker of sudomotor dysfunction over time. [3]
Sensitivity and Specificity Estimates for Sudoscan
The diagnostic thresholds and reference standards vary by study and neuropathy phenotype. [1] [2] [4]
Diabetic peripheral neuropathy (DPN)
Foot ESC was reported to have sensitivity 87.5% and specificity 76.2% for classifying DPN in a diagnostic study using a feet ESC threshold. [4] In type 1 diabetes, sudomotor dysfunction defined by foot ESC <60 µS had sensitivity 72.8% and specificity 61.4% for detecting clinical DPN when compared with Michigan Neuropathy Screening Instrument (MNSI)-defined clinical neuropathy. [1]
Small-fiber neuropathy (SFN) and diabetic small-fiber neuropathy
A device-validation study comparing a home device (Body Scan) against a Sudoscan reference reported sensitivity and specificity for detecting moderate or severe SFN using Sudoscan-defined ESC cutoffs (feet ESC ≤70 µS for “at least moderate” and feet ESC ≤50 µS for “severe”). [4] For “at least moderate” SFN: sensitivity 0.91 and specificity 0.97. [4] For “severe” SFN: sensitivity 0.91 and specificity 0.99. [4]
Transthyretin familial amyloid polyneuropathy (TTR-FAP) and dysautonomia
In a diagnostic study of TTR-FAP Val30Met carriers, feet ESC showed sensitivity 76% and specificity 85% for detection of dysautonomia. [2] In a study distinguishing TTR-FAP from chronic inflammatory demyelinating polyneuropathy (CIDP), feet ESC <64 µS had sensitivity 89% and specificity 96% to differentiate CIDP from TTR-FAP. [5] In a single-center ATTRv experience, feet ESC <70.5 µS had sensitivity 89.7% and specificity 84.6% to discriminate asymptomatic carriers from ATTRv patients. [6]
Interpretation of Specificity and Sensitivity Patterns
Sudoscan demonstrates higher sensitivity than specificity across several published neuropathy cohorts, which implies a greater probability of false-positive sudomotor impairment relative to false-negative results in some settings. [1] [2] [4] [5] Some cohorts demonstrate strong discriminative ability for autonomic dysfunction in TTR-FAP, with sensitivity and specificity frequently in the mid-to-high ranges for feet ESC cutoffs. [2] [5]
Important Nuances and Limitations Reported in the Evidence
ESC cutoffs differ across studies, including thresholds such as 60 µS for sudomotor dysfunction in type 1 diabetes and 50 µS or 70 µS cutoffs for defining moderate versus severe SFN in validation work. [1] [4] Reference standards differ across studies, including MNSI-defined clinical DPN, dysautonomia definitions, and diagnostic differentiation between neuropathy syndromes such as TTR-FAP versus CIDP. [1] [2] [5] In small-sample longitudinal chemotherapy neuropathy work, Sudoscan ESC profiles changed after treatment, but the study size was small (n=18), which limits precision for diagnostic performance estimates. [3]
Evidence Summary for Practical Clinical Use
Sudoscan provides an objective sudomotor biomarker that has been associated with clinical DPN detection and with autonomic dysfunction in TTR-FAP. [1] [2] Sudoscan diagnostic performance for ESC-based phenotypes depends on the neuropathy population studied and on the ESC thresholds used for sensitivity/specificity calculations. [1] [2] [4] Sudoscan has been explored as an accessible test for screening or monitoring sudomotor impairment in clinical and research settings where small-fiber or autonomic involvement is suspected. [1] [2] [3]
Evidence Sources Used for Sensitivity and Specificity Estimates
Diabetes and DPN-focused sensitivity/specificity estimates were taken from diagnostic studies reporting foot ESC thresholds and performance metrics against clinical neuropathy reference standards. [1] [4] SFN-focused sensitivity/specificity estimates were taken from validation work using Sudoscan-defined ESC cutoffs and a reference sudomotor device. [4] TTR-FAP and dysautonomia sensitivity/specificity estimates were taken from diagnostic studies and cohort comparisons using ESC thresholds to separate symptomatic versus asymptomatic stages, dysautonomia status, and neuropathy syndromes. [2] [5] [6]